A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT05241093 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Acute Myeloid Leukemia (AML)

Interventions

DRUG: HYML-122; cytarabine

Sponsor

Tarapeutics Science Inc.